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Abstract
Amplification of the MYCN oncogene is strongly associated with poor prognosis in neuroblastoma (NB). In addition
to MYCN amplification, many studies have focused on identifying patients with a poor prognosis based on gene
expression profiling. Themajority of prognostic signatures today are comprised of large gene lists limiting their clinical
application. In addition, although of prognostic significance, most of these signatures fail to identify cellular processes
that can explain their relation to prognosis. Here, we determined prognostically predictive genes in a data set con-
taining 251 NBs. Gene Ontology analysis was performed on significant genes with a positive hazard ratio to search for
cellular processes associated with poor prognosis. An enrichment in ribonucleoproteins (RNPs) was found. Genes
involved in the stabilization and formation of the central small nucleolar RNP (snoRNP) complex were scrutinized using
a backward conditional Cox regression resulting in an snoRNP signature consisting of three genes: DKC1, NHP2, and
GAR1. The snoRNP signature significantly and independently predicted prognosis when compared to the established
clinical risk factors. Association of snoRNP protein expression and prognosis was confirmed using tissue micro-
arrays. Knockdown of snoRNP expression in NB cell lines resulted in reduced telomerase activity and an increase
in anaphase bridge frequency. In addition, in patient material, expression of the snoRNP complex was significantly
associated with telomerase activity, occurrence of segmental aberrations, and expression-based measurements of
chromosomal instability. Together, these results underscore the prognostic value of snoRNP complex expression in
NB and suggest a role for snoRNPs in telomere maintenance and genomic stability.
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Introduction
Neuroblastoma (NB) is the second most common childhood solid
tumor and is responsible for 15% of cancer-related deaths in children
[1,2]. NBs display a range of genetic alterations including amplifica-
tion of the MYCN oncogene, deletions of 1p and 11q, as well as
gains of 17q [3,4]. In general, low-stage (stage 1, 2, and 4S) NBs
harbor relatively few genomic alterations, and those that are detected
are most often numerical changes, i.e., gains and/or losses of whole
chromosomes. High-stage (stage 3 and 4) NBs, however, are asso-
ciated with chromosomal instability and a relatively higher frequency
of segmental aberrations [5,6]. Although increased genetic complex-
ity has been observed in high-stage tumors, the mechanism behind
the accumulation of chromosomal aberrations in these tumors has
been poorly described.
Telomeres are protective repeats of TTAGGG sequences located at
the end of chromosomes [7]. One important function of the telomere
is to prevent end-to-end joining of chromosomes, which otherwise
could lead to the accumulation of chromosomal breaks during mitosis
[8]. In normal progenitor cells, the formation and maintenance of
telomeres is primarily carried out by the enzymatic complex telomerase
[9]. Tumor cells, however, in addition to the conventional telomerase-
dependent telomere maintenance can also posses the ability to elongate
the telomeric DNA through a process known as alternative lengthen-
ing of telomeres (ALT). In NB specifically, both ALT and telomerase
have been described to be prognostically relevant [10,11] and studies
in other cancer types suggest that ALT and telomerase activity may
not be mutually exclusive [12–14]. Telomerase is comprised of a
variety of subunits, including the protein-enzymatic subunit TERT,
the guiding RNA subunit TERC, as well as supportive protein com-
plexes such as small nucleolar RNPs (snoRNPs), shelterin, and the
ATPases pontin and reptin [15,16]. It has previously been shown that
the presence of all of these subunits is required for a functional telo-
merase complex [17]. While TERT is responsible for the enzymatic
activity of the complex, TERC acts as a template and is required for
guidance of the complex to the telomeres. With regard to the snoRNPs,
their involvement has been associated with stabilization of TERC,
allowing for proper docking of the RNA subunit with the enzymatic
TERT. Both the interactions of DKC1 with TERC as well as further
interaction of DKC1/TERC with TERT are facilitated by the ATPases
pontin (also called RUVBL1) and reptin (also called RUVBL2). Once
located at the telomeres, proteins from the shelterin complex aid in
stabilizing the 3′ chromosome by altering the structural conformation
of the telomere and thereby preventing it from being recognized as
damaged DNA [16].
In NB patients, increased maintenance of telomeres through elevated
telomerase activity or activation of ALT as well as longer telomeres in
tumor cells is associated with a poor prognosis [10,11,18]. Some con-
troversy remains regarding what regulates the activity of telomerase
in high-stage NBs, although there have been several reports showing
that TERT can be regulated by the MYC pathway [19–21]. In this
study, we report that the expression of proteins involved in the for-
mation and stabilization of the snoRNP complex is elevated in high-
stage NBs and is associated with a poor prognosis. Knockdown of
DKC1, the central snoRNP subunit, in NB cells led to decreased levels
of TERC and a significant reduction of telomerase activity. Under
these conditions, we also noted an increase in the frequency of ana-
phase bridges. In addition, we observed a positive correlation be-
tween snoRNP expression and telomerase activity in a panel of NB
tumor samples. This suggests that elevated snoRNP expression in
high-stage NB tumors may contribute to maintenance of telomere
length and in doing so prevent detrimental genomic events at later
stages of the disease.
Materials and Methods
Cell Culture
SK-N-BE(2)C and SK-N-SH NB cells (American Type Culture
Collection, Boras, Sweden) were cultured in minimum essential me-
dium and RPMI 1640 growth medium, respectively. Growth medium
was supplemented with 10% FBS and 1% penicillin-streptomycin.
Cells were cultured in a humidified incubation chamber maintained
at 37°C with 5% CO2 and 95% air (approximately 21% O2).
snoRNP Signature Generation
Using a publicly available data set containing 251 NB tumors
(Array Express Accession No. E-TABM-38; http://www.ebi.ac.uk/
arrayexpress/) [22], all genes were analyzed using the Cox propor-
tional hazards ratios. Genes were separated into those with positive
hazard ratios (HR; poor prognosis) and negative HRs (good prog-
nosis). Genes were then further ranked according to significance of
prognostic value based on a Bonferroni-corrected P value. Using a
significance cutoff of P < .0001, a Gene Ontology (GO) analysis was
performed, using the functional annotation tool in DAVID [23], on
genes with a positive HR (n = 643). After finding a significant en-
richment of RNP-associated genes, a literature review was performed
to examine genes essential for the formation and/or stabilization
of the central RNP complex. These identified genes were then dis-
criminated using a backward conditional Cox regression model re-
sulting in three significant genes. Calculating the mean rank values of
these three genes then generated the snoRNP signature score.
Gene Expression Arrays
Using the 251-tumor data set (Array Express Accession No.
E-TABM-38; http://www.ebi.ac.uk/arrayexpress/) [22], the three-gene
snoRNP signature score was used to divide patients into high versus
low expressing groups determined by the median expression of the
signature score. Overall survival (OS) and event-free survival (EFS)
were examined by Kaplan-Meier analysis.
Validation of the snoRNP signature was performed in an in-
dependent data set consisting of 88 tumors (NCBI GEO Accession
No. GSE 16476; http://www.ncbi.nlm.nih.gov/geo/) [5]. Kaplan-
Meier analysis was performed as described above. Mantel-Cox log-rank
analysis was performed and P values < .05 were considered significant.
To determine the independent predictive capacity of examined
variables in both data sets, multivariate Cox regression analysis
was performed. International Neuroblastoma Staging System (INSS)
stage was examined as categorical. P values of HRs < 0.05 were
considered significant.
Single Nucleotide Polymorphism (SNP) Array
Two hundred nanograms of DNA from 84 of the 88 tumors
used for gene expression analysis (GSE 16476) [5] was hybridized to
Illumina Human CNV370/660/Omnia BeadChips (Illumina Inc,
San Diego, CA) and processed according to the manufacturer’s recom-
mendations. Normalized allelic intensity values were subjected to an ad-
ditional normalization step using the tQN software (http://baseplugins.
thep.lu.se/wiki/se.lu.onk.IlluminaSNPNormalization) for estimation
of B-allele frequency and log2 ratio. Constitutional copy number
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polymorphisms were excluded on the basis of comparison with the
Database ofGenomicVariants (http://projects.tcaq.ca/variation,GRCh37
genome build). Identified segments of copy number imbalances by the
B-allele frequency segmentation software (http://baseplugins.thep.
lu.se/wiki/se.lu.onk.BAFsegmentation) were in addition manually
analyzed and verified with the use of BeadStudio 3.1 software with
Illumina Genome Viewer.
siRNA Transfection for Quantitative Real-Time Polymerase
Chain Reaction Analysis
Cells were seeded in six-well plates at a density of 150,000 cells
per well in medium (as described above). Cells were left to attach
overnight. The medium was then removed and replaced with 2 ml
of Opti-MEM (Invitrogen, Stockholm, Sweden). Transfection was
carried out using Lipofectamine 2000 transfection agent and two pre-
designed silencer select siRNAs (Invitrogen) targeting each gene as well
as a negative control scrambled siRNA (siRNA Negative Control #2).
An siRNA concentration of 10 nM was used for all transfections. Cells
were left in the transfection medium for 6 hours after which the trans-
fection medium was removed and replaced with 2 ml of normal cell cul-
ture medium. Cells were then left in standard culture conditions for 48
or 72 hours before harvest.
Quantitative Real-Time Polymerase Chain Reaction
Cells were harvested and lysed in TRIzol (Invitrogen). Five fresh-
frozen tumor tissue samples (Ethical Permit LU 389-98 and parent
consent) were first treated with RNAlater-ice (Invitrogen) according to
the manufacturer’s protocol. Tissue samples were then homogenized
with a scalpel on dry ice and lysed in TRIzol. The aqueous phase
was obtained using chloroform at a concentration of 200 μl per 1 ml
of TRIzol. RNA from this phase was extracted using RNeasy spin col-
umns (Qiagen, Hilden, Germany) according to the manufacturer’s pro-
tocol. Extracted RNA was DNAse treated and washed using Microcon
spin columns (Millipore, Solna, Sweden). cDNA synthesis was per-
formed using random primers and Multitranscribe Reverse Transciptase
(Applied Biosystems, Stockholm, Sweden). Resulting cDNA was
analyzed using SYBR Green PCR Master Mix (Applied Biosystems)
on a 7300 Sequence Detection System (Applied Biosystems). The com-
parative C t method was used to compare relative expression levels [24].
Three housekeeping genes (UBC, YWHAZ, and SDHA) were used for
normalization. Primer sequences and assay efficiencies are displayed in
Table W2.
Anaphase Bridge Analysis
Cells were seeded in six-well plates at a density of 75,000 cells per
well on sterilized glass coverslips and siRNA transfections were carried
out as above. Seventy-two hours post transfection, cells were fixed on
the coverslips in 3:1 methanol/glacial acetic acid for 20 minutes. Fixed
cells were then stained using hematoxylin and eosin. Scoring of the
stained cells was performed manually, counting the number of nor-
mal and abnormal (anaphase bridge) anaphase cells. The counts in
each group were compared using Student’s t test, where P < .05 was
considered significant.
Telomeric Repeat Amplification Protocol
For the five tumor tissue samples examined [same tumors used for
quantitative real-time polymerase chain reaction (QPCR) analysis],
approximately 30 mg of tissue was collected from each sample on
dry ice. For cell line experiments, cells were seeded in six-well plates
at a density of 200,000 cells per well. siRNA transfections were car-
ried out as described above. Cells were cultured for 48 hours after
transfection before harvesting. Harvesting and telomeric repeat ampli-
fication protocol (TRAP) assays were carried out according to the
manufacturer’s protocol (Millipore; TRAPeze XL Telomerase Detection
Kit). In brief, homogenized tissue or cells were harvested and lysed in
CHAPS lysis buffer supplemented with RNase inhibitor at a concen-
tration of 200 units/ml (Life Technologies, Stockholm, Sweden). Debris
was pelleted by centrifugation and protein/supernatant was transferred
to a new tube. Protein concentration of the supernatant was determined
using a spectrophotometer (Thermo Scientific Nanodrop ND-1000).
PCR was then performed in a thermocycler (Eppendorf Mastercycler
Gradient) using TRAPeze XL reaction mix, Taq polymerase (Life Tech-
nologies), and sample extract. Following PCR, relative telomerase activity
was determined using a fluorescence plate reader (BioTek Synergy 2).
Tissue Microarray
Paraffin-embedded cores from 42 NB tumors were obtained from
the Versteeg laboratory in Amsterdam. Immunohistochemical stain-
ing was performed using an anti-DKC1 antibody (Sigma-Aldrich,
Stockholm, Sweden; HPA000447) diluted 1:100 and with an anti-
NHP2 antibody (Biosite, Stockholm, Sweden; 15128-1-AP) diluted
1:200. Stainings were performed without knowledge of the biologic
or clinical characteristics of any specific cores. Signed consent was ob-
tained from each patient’s parents for documentation, biologic studies,
and analysis. The regional ethics review boards of the participating
institutes have approved the study. Cores were scored on a scale from
0 to 3 based on intensity of staining in tumor cells. Scoring was per-
formed independently by two persons. Kaplan-Meier analysis was per-
formed based on tissue microarray (TMA) scores, and Mantel-Cox
log-rank P value < .05 was considered significant. Additional TMAs
from DP-UV in Valencia with 68 cases of NB were used (Ethical
Approval No. 59CI8ABR2002). The TMA sections were analyzed
by DKC1 immunohistochemistry as described above.
Statistical Analyses
The significance of prognostic information given by gene expression
in array data was assessed using the Cox proportional HRs and
corresponding Bonferroni-corrected P values. Independent contribu-
tion of genes and the reduction of number of genes in the snoRNP
signature score were determined using backward conditional Cox
regression analysis. EFS and OS analyses were performed using
Kaplan-Meier survival plots and corresponding Mantel-Cox log-rank
tests. Independence of the snoRNP signature score from clinical
parameters and other NB defining characteristics was determined using
entered Cox regression analysis. Correlation analyses were determined
using Pearson product-moment correlation coefficients. Group com-
parisons in cell line experiments were carried out using Student’s t test.
Results
Enrichment of snoRNPs among Prognostically Significant
Genes in NB
To search for processes associated with prognosis in NB, a gene
expression data set consisting of 251 tumors was examined [22]. We
employed Cox proportional HR test on all genes to find the most
significant predictive genes in the data set. Background-corrected GO
analysis was then performed on all genes with a positive HR and
a significance cutoff of P < .001 (Table W1) to search for functional
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clusters of genes associated with poor prognosis. Upon GO analysis, a
significant enrichment of RNP and RNP complex–associated genes was
found (Table 1A). Interestingly, top ranking among these enriched
genes was DKC1, the core enzymatic subunit of the snoRNP complex
[25]. Further examination of the gene list revealed that four additional
genes (GAR1,NHP2, RUVBL1, and RUVBL2) crucial to the formation
and/or stabilization of the snoRNP complex [25–28] were included
among the top predictors of poor prognosis. When performing a back-
ward conditional Cox regression analysis of the five genes, three of the
genes (DKC1, GAR1, and NHP2) were found to be independent pre-
dictors of patient survival (Table 1B). Interestingly, these genes com-
prise three of the four core components of the snoRNP complex, the
fourth of which, NOP10, was not present in the data set.
snoRNP Signature Score Is an Independent Predictor
of Prognosis
Next, we calculated an snoRNP signature score, based on the mean
rank values of DKC1, GAR1, and NHP2. Application of the snoRNP
signature score significantly predicted patient OS and EFS (Figure 1,
A and B; log-rank P = 1.3 × 10−10 and 8.5 × 10−12, respectively). Taking
into consideration the heavy influence MYCN amplification has on
progression and prognosis of the disease [4], we examined the predictive
capacity of the snoRNP gene signature in all patients not harboring
an MYCN amplification. Once again, the snoRNP signature was sig-
nificantly associated with OS and EFS prognoses (Figure 1, C and D;
log-rank P = 3.0 × 10−6 and 1.9 × 10−7, respectively). In addition, when
compared to bothMYCN amplification as well as anNB-derivedMYC
pathway activity score [29] in a multivariate analysis, the snoRNP
signature was independently associated with prognosis [Figure W1C ;
HR = 17.3, 95% confidence interval (CI) = 2.2–135.7]. In the clinic,
it is important to identify the subgroup of high-risk patients that does
not respond to intense treatment and displays a dismal prognosis. We
therefore examined the prognostic value of the snoRNP signature score
in the subset of high-stage (stage 4) patients. Once again, the snoRNP
signature significantly identified a subgroup of patients with a worse
prognosis (Figures W1A and 1E ; log-rank P = 3.0 × 10−5). In addi-
tion, upon performing a multivariate Cox regression analysis across
all patients, snoRNP signature score was an independent prognostic
marker when compared to the clinically used parameters age at diag-
nosis, INSS stage, and MYCN amplification (Figure 1F ; HR = 846.9,
95% CI = 31.7–22620.4).
To validate the predictive capacity of the snoRNP signature, a sec-
ond independent data set consisting of 88 tumors was examined [5].
As was found in the 251-tumor data set, snoRNP signature score
was a significant predictor of both OS and EFS (Figure 2, A and
B, log-rank P = 3.6 × 10−9 and 2.8 × 10−7, respectively). This asso-
ciation to prognosis was independent of MYCN amplification status
(Figure 2, C and D, log-rank P = 1.0 × 10−4 and 0.003, respectively).
Furthermore, the snoRNP signature displayed independent prog-
nostic value when compared to MYCN amplification and MYC path-
way activity (Figure W1D; HR = 8.2, 95% CI = 1.5–45.7). In
addition, in this validation cohort, the snoRNP signature score could
significantly identify a subgroup of ultrahigh-risk patients within pa-
tients already classified as stage 4 (Figures W1B and 2E , log-rank
P = .009). As in the 251-tumor data set, the snoRNP score fell out
as an independent prognostic marker when compared to the com-
monly used clinical parameters (Figure 2F ; HR = 59580, 95% CI =
12.4–2.9 × 108).
snoRNP Protein Expression Predicts Patient Survival and
Correlates with snoRNP Expression Signature
To determine if the expression of snoRNPs also correlated to prog-
nosis at the protein level, a TMA consisting of 42 tumors (42 of the
88 tumors included in [5]) was stained for both the core subunit DKC1
and cofactor NHP2. Tumor cell staining intensity was scored on a
scale from 0 to 3 (Figure 3A). Indeed, both DKC1 and NHP2 protein
expression significantly predicted patient survival (Figure 3, B and C ;
log-rank P = .011, log-rank P = .022, respectively). In an independent
TMA consisting of 68 tumors, DKC1 staining intensity again displayed
a significant association with patient survival (Figure 3D; log-rank P =
.020). In addition, comparing matched gene expression data with pro-
tein staining in the 42 examined tumors, protein staining displayed sig-
nificant positive correlations with snoRNP signature score for both
DKC1 and NHP2 (Figure 3, E and F , respectively). The observation
of a strong correlation between mRNA and protein expression is of
importance. It indicates that the extrapolation from mRNA to protein
expression can be made and it allows for utilization of both mRNA and
protein-based assessment of snoRNP expression levels in NBs.
DKC1 Regulates Telomerase Activity in NB Cell Lines
After establishing that snoRNP expression is significantly associated
with outcome, we sought to clarify what function this complex may
have in aggressive NBs. It has previously been shown in multiple cel-
lular systems that snoRNPs, specifically DKC1, are required for the
formation of a functional telomerase complex [15]. Taking this into
consideration, along with previous implications of telomere regulation
in aggressive NBs [10,11,18], we examined whether the snoRNP core
subunit DKC1 modulated telomerase activity in NB. Upon siRNA-
mediated knockdown of DKC1 in the NB cell lines SK-N-BE(2)c
Table 1. Prognostically Significant Genes Display Enrichment for RNPs and RNP Complexes.
(A)
Ontology Cluster Enrichment Score: 13.02
Ontology P Value Benjamini
GO:0030529∼RNP complex 1.65E − 33 9.31E − 32
RNP 3.98E − 31 3.72E − 29
Ribosomal protein 1.46E − 21 6.83E − 20
GO:0005840∼ribosome 8.11E − 21 2.75E − 19
GO:0003735∼structural constituent of ribosome 4.14E − 20 1.27E − 17
GO:0006412∼translation 6.88E − 17 1.29E − 14
GO:0033279∼ribosomal subunit 8.07E − 13 1.82E − 11
GO:0006414∼translational elongation 1.12E − 11 7.25E − 10
Hsa03010:Ribosome 2.27E − 11 9.02E − 10
Protein biosynthesis 3.90E − 11 8.59E − 10
Ribosome 2.26E − 10 4.45E − 09
GO:0044445∼cytosolic part 1.42E − 09 2.30E − 08
GO:0022626∼cytosolic ribosome 9.51E − 09 1.47E − 07
GO:0015935∼small ribosomal subunit 1.04E − 06 1.10E − 05
GO:0015934∼large ribosomal subunit 2.07E − 06 2.12E − 05
GO:0005198∼structural molecule activity 3.23E − 05 0.001325134
GO:0022627∼cytosolic small ribosomal subunit 4.66E − 05 3.95E − 04
(B)
Gene Symbols HR Bonferroni
DKC1 5.138386213 1.13E − 12
GAR1 5.058835777 1.35E − 11
NHP2 4.371744327 3.71E − 07
(A) GO cluster with subcategories and corresponding P values and corrected P values (Benjamini).
(B) Central RNP complex subunits with corresponding HR and Bonferroni-corrected P values.
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Figure 1. Testing of snoRNP signature score—snoRNP score predicts prognosis and is independent of MYCN status. (A–D) Kaplan-
Meier analyses and corresponding log-rank P values for OS and EFS according to snoRNP signature score. Group divisions decided
by median snoRNP score (HIGH, above median; LOW, below median). Analyses were performed on all 251 patients (A–B) as well as the
subgroups of patients without MYCN amplification (C–D, n = 219) and stage 4 patients (E, n = 67). (F) Multivariate Cox regression
analysis including snoRNP score, age of diagnosis, INSS stage, and MYCN amplification status. Accompanying HRs (Exp(B)) with
95% CIs and significance values are provided.
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Figure 2. Validation of snoRNP signature score—snoRNP score predicts patient prognosis and is independent of MYCN status. (A–D)
Kaplan-Meier analyses and corresponding log-rank P values for OS and EFS according to snoRNP signature score. Group divisions decided
by median snoRNP score (HIGH, above median; LOW, below median). Analyses were performed on all 88 patients (A–B) as well as the
subgroups of patients without MYCN amplification (C–D, n = 72) and stage 4 patients (E, n = 40). (F) Multivariate Cox regression analysis
including snoRNP score, age at diagnosis, INSS stage, and MYCN amplification status. Accompanying HRs (Exp(B)) with 95% CIs and
significance values are provided.
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and SK-N-SH (MYCN-amplified and non-amplified, respectively), we
detected a significant reduction in expression levels of the telomerase
RNA subunit TERC in both cell lines (Figure 4, A–C ). In addition,
assessment of telomerase enzymatic activity using the TRAP assay re-
vealed reduced telomerase activity in both the MYCN-amplified and
non-amplified cell systems upon knockdown of DKC1 (Figure 4D).
Expression analysis of the telomerase enzymatic subunit TERT did,
however, not reveal modulation upon DKC1 depletion (Figure 4E ),
supporting the notion that altered DKC1 levels regulate telomerase
activity in a manner independent of TERT modulation. Despite pre-
vious reports suggesting TERT induction through the MYC pathway
[19–21], TERT expression was substantially higher in the MYCN–
non-amplified SK-N-SH cells when compared to theMYCN-amplified
SK-N-BE(2)C cells. Taking into consideration the similar levels of
telomerase activity detected between the two cell lines (Figure 4D), this
surprising difference in TERT expression further supports the idea that
telomerase activity levels in NB do not mirror TERT expression levels.
Interestingly, the observed effects on TERC and telomerase activity
were detected despite a modest knockdown of DKC1 at the protein
level, suggesting a potential rate-limiting role of DKC1 in telomerase
regulation. In addition, the previously reported importance of telome-
rase activity in NB and the independence of snoRNP score from TERT
expression (Figure W1, C and D) support the notion that snoRNPs
independently modulate telomerase activity levels in NB. To evaluate
the association between snoRNP expression and telomerase activity
in vivo, a panel of five NB tumors was examined. QPCR-based analysis
of snoRNP (DKC1, GAR1, and NHP2) expression displayed a signifi-
cant positive correlation to telomerase activity (Figure 4F ; r = 0.914,
P = .029) as determined by TRAP assay.
Loss of DKC1 Results in Increased Frequency of
Anaphase Bridges
Considering the importance of telomere maintenance during re-
peated cell divisions [30], we examined whether the observed reduc-
tion in telomerase activity following DKC1 depletion may have an
effect on the ability of NB cells to undergo mitosis. It has previously
been shown that defects in telomere maintenance can result in the
formation of anaphase bridges during the separation of dividing cells
[31]. In both cell lines, even modest DKC1 reduction resulted in a
significant increase in the frequency of anaphase bridge formation
(Figure 5, A and B). This supports the idea that DKC1 knockdown
resulted in failure of chromosome protection because of a lack of
telomere maintenance.
snoRNP Expression Correlates with Segmental Aberrations
and Chromosomal Instability
Taking into consideration the consequences of altered DKC1 ex-
pression on telomerase activity and chromosome separation during cell
Figure 3. snoRNP protein expression is associated with prognosis and correlates with snoRNP signature score. (A) Representative
images of DKC1 (top) and NHP2 (bottom) stainings with corresponding TMA score from the TMA consisting of 42 tumors (AMS 42).
(B and C) Kaplan-Meier analyses for OS according to DKC1- and NHP2-TMA scores, respectively. (D) Kaplan-Meier analysis for OS accord-
ing to of DKC1-TMA scores in an independent TMA consisting of 68 tumors (VAL 68). Corresponding log-rank P values are provided. (D and
E) Box plots of gene expression based snoRNP signature score versusmatched AMS 42 DKC1-TMA score and NHP2-TMA score, respec-
tively. Boxes represent the interquartile range with a median dividing line. Whiskers extend to minimum and maximum values. Relative
Pearson’s correlation coefficient (r) and corresponding P values are provided.
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division, we hypothesized that divergent expression of snoRNPs might
be associated with an overall increase in genetic aberrations. We
therefore examined the relationship between snoRNP expression and
various measurements of genomic stability. SNP array data matched
to 84 of the 88 tumors used for gene expression analysis (Figure 2)
[5] were analyzed for genetic events in correlation to snoRNP signature
score. The snoRNP signature score displayed a significant positive
correlation with the presence of segmental aberrations, while displaying
a negative correlation to numerical changes (Figure 5C). Furthermore,
within the 88 tumors, we found a significant positive correlation
between the snoRNP signature score and genomic complexity (GC)
as measured by implementation of a previously published GC signa-
ture (Figure 5D, top panel ) [32]. The observed positive correlation
between snoRNP score and GC signature was further validated in
the 251-tumor data set (Figure 5E , top panel ). Interestingly, even
within stage 4 tumors, snoRNP score and GC signature were positively
correlated (Figure 5, D and E , bottom panels).
Discussion
Predicting NB patient prognosis based on multigene signatures has
been widely explored and, in some instances, with great success
Figure 4. Knockdown of DKC1 results in reduced telomerase activity. SK-N-BE(2)C and SK-N-SH NB cell lines were treated with control
siRNA or siRNAs targeting DKC1 and harvested 48 hours post transfection (A–C). (A) QPCR analysis of DKC1 mRNA expression relative
to siControl-treated cells in each cell line. (B) Western blot analysis of DKC1 protein analysis 48 and 72 hours post transfection. (C) QPCR
analysis of TERC expression relative to siControl-treated cells in each cell line. (D) Telomerase activity asmeasured by TRAP assay, displayed
as relative to siControl-treated SK-N-BE(2)C cells. (E) QPCR analysis of TERT expression relative to siControl-treated SK-N-BE(2)C cells. Error
bars represent the SD of the mean of three independent experiments. Treatments were compared within cell lines using Student’s t test
(*P< .05; **P< .01). (F) Scatter plot of snoRNP signature score versus telomerase activity in a panel of five fresh-frozen NB tumors. Values
are relative to highest values detected among the tumor panel with regard to snoRNP score and telomerase activity. Pearson’s correlation
coefficient (r) and corresponding P values are displayed.
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[33–39]. With the common methods used to compile these gene sig-
natures, comparing expression patterns based on differential survival
in the patients, the gene lists often consist of a large number of genes
without clear commonality with regard to functions and/or molecular
pathways. Using NB gene expression arrays, we searched for com-
monalities among the top prognostic genes with use of GO analysis.
We further describe a three-gene signature consisting of genes central
in the formation and stabilization of the snoRNP protein complex.
The snoRNP signature displayed highly significant prognostic value
and was an independent predictor of poor prognosis when compared
Figure 5. snoRNP expression is associated with genetic instability and altered expression results in mitotic dysfunction. SK-N-BE(2)C and
SK-N-SH cells were treated with control siRNA or siRNA targeting DKC1. Cells were fixed 78 hours post transfection. (A) Hematoxylin
and eosin staining of SK-N-BE(2)C cells in anaphase, displaying both a normal (left) and an abnormal/bridged (right) anaphase. (B) Relative
quantification of anaphase bridges in SK-N-BE(2)C (top) and SK-N-SH (bottom) cells after respective siRNA treatments. Error bars represent
the SD of the mean of three independent experiments. Treatments were compared using Student’s t test (*P< .05; **P< .01). (C) Expres-
sion data and matched SNP data from the Versteeg 88 data set were merged (n = 84). (C) Left: Scatter plot of snoRNP signature score
versus number of segmental aberrations. Right: Scatter plot of snoRNP signature score versus number of numerical changes. (D and E)
Scatter plots of snoRNP signature score versus GC signature score in the Versteeg and Oberthuer data sets, respectively. Analyses were
performed in all patients (top panels) and specifically in stage 4 patients (bottom panels). Pearson’s correlation coefficient (r) and
corresponding P values are displayed for each scatter plot (C–E).
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with the common clinically used parameters, such as age at diagnosis,
INSS stage, andMYCN amplification, as well as MYC pathway activity
and TERT expression. The fact that the signature consists of only three
genes can allow for simple PCR-based patient testing, asGarcia et al. have
recently shown [40]. In further support of its clinical relevance, applica-
tion of the signature to pre-defined stage 4 patients identified an ultra-
high-risk group of patients (OS < 20%), who display a dismal prognosis
despite intense treatment regimens. To identify this patient group at di-
agnosis could justify inclusion of these patients in clinical trials with new
treatment strategies and/or therapies.
Previous studies have displayed an association between telomere
maintenance and prognosis in NB [10,11,18]. The mechanism by
which telomerase activity is regulated in high-stage tumors has,
however, remained elusive. In addition, how telomerase activity con-
tributes to tumor progression has been a topic of debate. Recent
studies have, however, shed some light on this question [41,42].
By employing a mouse model system for prostate cancer and T cell
lymphomas, it was shown that a lack of telomerase activity during
early stages of tumor development promoted tumor formation. Loss
of telomeres resulted in formation of breakage-fusion bridge cycles
during mitosis leading to the accumulation of amplifications and
deletions at the affected sites. Although accumulation of such genetic
events may be beneficial during early progression, the acquisition
of many genetic events can lead to cellular crisis and initiation of
cell death. As a result, high-risk tumors require a mechanism to
stabilize the genome to prevent cellular crisis from occurring. In the
aforementioned studies, it was shown that reactivation of telome-
rase activity through conditional expression of TERT stabilized the
genome in these genetically complex tumors, preventing activa-
tion of apoptotic pathways and allowing for dissemination of the
disease [41,42].
We, however, do not find TERT expression to be consistently
associated with prognosis in NB (Figure W1, A and B). However,
we do show a significant association between the expression of the
telomerase-associated snoRNP complex and survival. Furthermore,
upon knockdown of the central snoRNP subunit DKC1, we observed
a significant reduction in expression of the telomerase RNA subunit
TERC accompanied by lower telomerase activity. This suggests a
potential role of DKC1 and other snoRNPs in the elevated telomerase
activity observed in advanced tumors. In line with this hypothesis,
decreased DKC1 expression resulted in an increased frequency of
anaphase bridge formation, a genetic event associated with loss of
telomeres resulting in increased chromosomal instability [31]. Inter-
estingly, loss of DKC1 and other snoRNPs such as NHP2 are asso-
ciated with dyskeratosis congenita, a disease characterized by a loss of
telomerase activity and early aging of the patients. In addition to early
aging, dyskeratosis congenita patients display an increased risk for
developing multiple cancer forms, which has been attributed to a
telomerase deficiency–dependent increase in genetic instability [43].
However, it has been reported in multiple cancer types (breast, colon,
and prostate), and now in line with our data in NB, that high DKC1
expression is associated with advanced disease and poor prognosis [44–
46]. Taken together, public data and our data suggest that similar to
the previously described model regarding TERT loss and reactivation,
a low expression of snoRNPs may allow for the development of genetic
alterations during pre-clinical tumor development. In advanced tu-
mors, a subsequent up-regulation of snoRNPs may aid in telomere
maintenance and stabilization of the genome, which in turn prevents
highly complex tumors from going into cellular crisis. This provides
an explanation for the poor prognosis and the high level GC signature
observed among patients with high snoRNP expression.
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Table W2. QPCR Primer Sequences.
Gene Forward Primer (5′–3′) Reverse Primer (5′–3′) Assay Efficiency
UBC ATTTGGGTCGCGGTTCTTG TGCCTTGACATTCTCGATGGT 0.94
SDHA TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCAT 0.95
YWHAZ ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAAACAGTAT 0.89
DKC1 GGACGGCATTGAGGTCAATC ATGGTCGCAGGTAGAGATGA 0.91
GAR1 GGTGAGAAAGGACCTCCAAGAG CTGAAACCACCACCTCTTCCTC 0.96
NHP2 CCTCACGCGGAAGCTCTACAAA CAGTGTGTCTCCTGCCAAAACC 0.86
TERC CGCTGTTTTTCTCGCTGACTT TGCTCTAGAATGAACGGTGGAA 0.85
TERT TGACACCTCACCTCACCCAC CACTGTCTTCCGCAAGTTCAC 0.86
Figure W1. snoRNP signature score prognostic value is independent of MYC pathway activity and TERT expression. (A and B) Kaplan-
Meier analyses and corresponding log-rank P values for EFS in stage 4 patients according to snoRNP signature score. Group divisions
decided by median snoRNP score (HIGH, above median; LOW, below median). Analyses were performed in the Oberthuer 251-tumor
data set (A) and the Versteeg 88-tumor data set (B). (C and D) Multivariate Cox regression analysis including snoRNP score, MYCN
amplification status, MYC pathway activity, and TERT mRNA expression. Accompanying HRs (Exp(B)) with 95% CIs and significance
values are provided. Analyses were performed in the Oberthuer 251-tumor data set (C) and the Versteeg 88-tumor data set (D).
